NAUT logo

Nautilus Biotechnology (NAUT) Company Overview

Profile

Full Name:

Nautilus Biotechnology, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

August 7, 2020

Indexes:

Not included

Description:

Nautilus Biotechnology is a company focused on developing advanced technology for protein analysis. They aim to improve understanding of proteins in biology and medicine, helping researchers discover new treatments and diagnostics. Their innovative platform offers detailed insights into protein functions and interactions.

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Oct 29, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Dec 5, 24 Goldman Sachs
Sell
Jun 27, 24 Guggenheim
Buy
Aug 3, 23 Morgan Stanley
Equal-Weight
Aug 3, 22 Morgan Stanley
Equal-Weight
Aug 3, 22 Goldman Sachs
Neutral
Jul 14, 22 Goldman Sachs
Neutral
Apr 13, 22 Goldman Sachs
Neutral
Jan 6, 22 Morgan Stanley
Equal-Weight
Nov 2, 21 Cowen & Co.
Outperform
Aug 4, 21 Goldman Sachs
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript
NAUT
seekingalpha.comOctober 29, 2024

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET Company Participants Ji-Yon Yi - Investor Relations Sujal Patel - Co-Founder and Chief Executive Officer Parag Mallick - Co-Founder and Chief Scientist Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Operator Good day everyone, and thank you for standing by and welcome to Nautilus Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know
Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know
Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know
NAUT
Zacks Investment ResearchMay 3, 2024

Nautilus Biotechnology (NAUT) has been upgraded to a Zacks Rank #2 (Buy), indicating increasing confidence in the company's earnings potential. This could lead to a rise in the stock price in the short run.

Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript
NAUT
Seeking AlphaApril 30, 2024

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) will be hosting its Q1 2024 Earnings Conference Call on April 30, 2024 at 8:30 AM ET. Presenting will be Sujal Patel, Co-Founder & CEO, Parag Mallick, Co-Founder & Chief Scientist, and Anna Mowry, CFO. Thank you for joining the call.

Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript
NAUT
Seeking AlphaFebruary 28, 2024

Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript

Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript
NAUT
Seeking AlphaOctober 31, 2023

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Carrie Mendivil - IR Sujal Patel - Co-Founder & CEO Parag Mallick - Co-Founder & Chief Scientist Anna Mowry - CFO Conference Call Participants Yuko Oku - Morgan Stanley Daniel Brennan - Cowen Ivy Kozlowski - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023
Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023
Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023
NAUT
GlobeNewsWireOctober 11, 2023

SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter before market open on Tuesday, October 31, 2023.

Nautilus Biotechnology, Inc. (NAUT) Q2 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q2 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q2 2023 Earnings Call Transcript
NAUT
Seeking AlphaAugust 2, 2023

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Carrie Mendivil - Investor Relations Sujal Patel - Co-Founder, Chief Executive Officer, President, Secretary & Director Parag Mallick - Co-Founder, Chief Scientist & Director Anna Mowry - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Dave Delahunt - Goldman Sachs Dan Brennan - Cowen Operator Thank you for standing by, and welcome to the Nautilus Biotechnology Second Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, today's program is being recorded.

Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023
Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023
Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023
NAUT
GlobeNewsWireJuly 11, 2023

SEATTLE, July 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter before market open on Wednesday, August 2, 2023.

Nautilus Biotechnology to Participate in Upcoming June Investor Conferences
Nautilus Biotechnology to Participate in Upcoming June Investor Conferences
Nautilus Biotechnology to Participate in Upcoming June Investor Conferences
NAUT
GlobeNewsWireMay 24, 2023

SEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences:

FAQ

  • What is the ticker symbol for Nautilus Biotechnology?
  • Does Nautilus Biotechnology pay dividends?
  • What sector is Nautilus Biotechnology in?
  • What industry is Nautilus Biotechnology in?
  • What country is Nautilus Biotechnology based in?
  • When did Nautilus Biotechnology go public?
  • Is Nautilus Biotechnology in the S&P 500?
  • Is Nautilus Biotechnology in the NASDAQ 100?
  • Is Nautilus Biotechnology in the Dow Jones?
  • When was Nautilus Biotechnology's last earnings report?
  • When does Nautilus Biotechnology report earnings?
  • Should I buy Nautilus Biotechnology stock now?

What is the ticker symbol for Nautilus Biotechnology?

The ticker symbol for Nautilus Biotechnology is NASDAQ:NAUT

Does Nautilus Biotechnology pay dividends?

No, Nautilus Biotechnology does not pay dividends

What sector is Nautilus Biotechnology in?

Nautilus Biotechnology is in the Healthcare sector

What industry is Nautilus Biotechnology in?

Nautilus Biotechnology is in the Biotechnology industry

What country is Nautilus Biotechnology based in?

Nautilus Biotechnology is headquartered in United States

When did Nautilus Biotechnology go public?

Nautilus Biotechnology's initial public offering (IPO) was on August 7, 2020

Is Nautilus Biotechnology in the S&P 500?

No, Nautilus Biotechnology is not included in the S&P 500 index

Is Nautilus Biotechnology in the NASDAQ 100?

No, Nautilus Biotechnology is not included in the NASDAQ 100 index

Is Nautilus Biotechnology in the Dow Jones?

No, Nautilus Biotechnology is not included in the Dow Jones index

When was Nautilus Biotechnology's last earnings report?

Nautilus Biotechnology's most recent earnings report was on Oct 29, 2024

When does Nautilus Biotechnology report earnings?

The next expected earnings date for Nautilus Biotechnology is Feb 28, 2025

Should I buy Nautilus Biotechnology stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions